By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

ACADIA Pharmaceuticals, Inc. 

3911 Sorrento Valley Boulevard

San Diego  California  92121   U.S.A.
Phone: 858-558-2871 Fax: 858-558-2872


SEARCH JOBS

ACADIA is a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders.

YEAR FOUNDED:

July 16, 1993

LEADERSHIP:

Founder: Mark Brann

CEO: Stephen Davis

CMO (Medical): Randall Owen

JOBS:

Please click here for Acadia Pharma job opportunities.

CLINICAL TRIAL:

Please click here for clinical trial information.


PRODUCTS:

All Products


Key Statistics


Email: lbarthelemy@acadia-pharm.com
Ownership: Public

Web Site: Acadia
Employees: 140
Symbol: ACAD
 




Segment
Drug Discovery

Collaborations

Allergan  Discovery of alpha adrenergic drug candidates that may represent a significant breakthrough in the treatment of neuropathic pain.

Allergan  Develop and commercialize selective muscarinic drugs for the treatment of glaucoma.

Allergan  The third collaboration is designed to leverage ACADIA's R&D platform to discover and develop new therapeutics predominantly in the area of pain.

Sunovion  ACADIA has formed a broad CNS collaboration with Sepracor for the discovery and development of new drug candidates against muscarinic receptors.





Company News
Acadia (ACAD) Initiates Phase II Trial Of Pimavanserin For Adjunctive Treatment In Patients With Major Depressive Disorder 12/1/2016 7:59:07 AM
Acadia (ACAD) Initiates Phase II Trial Of Pimavanserin For Adjunctive Treatment In Patients With Negative Symptoms Of Schizophrenia 11/15/2016 11:08:33 AM
Acadia (ACAD) Reports Third Quarter 2016 Financial Results 11/8/2016 10:44:17 AM
Acadia (ACAD) Initiates Phase III Trial Of Pimavanserin For Adjunctive Treatment In Patients With Schizophrenia 11/3/2016 11:30:59 AM
Acadia (ACAD) To Announce Third Quarter 2016 Financial Results On November 7, 2016 11/1/2016 11:45:18 AM
Acadia (ACAD) Initiates Phase II Study Of Pimavanserin In Alzheimer’s Disease Agitation 10/31/2016 9:13:35 AM
Acadia (ACAD) Receives California Life Sciences Association’s 2016 Pantheon Dina Award For Outstanding Therapeutic Product For NUPLAZID 10/11/2016 10:57:10 AM
Acadia (ACAD) Sponsors National Parkinson Foundation’s Caregiver Summit 9/19/2016 11:59:50 AM
Acadia (ACAD) To Present At The Morgan Stanley Global Healthcare Conference On September 12, 2016 9/6/2016 11:06:21 AM
Acadia (ACAD) Announces Full Exercise Of Underwriters' Option To Purchase Additional Shares 8/24/2016 9:52:02 AM
12345678910...
//-->